Back to search results

Comparing Treatments for Early-Stage Liver Cancer with Low Albumin

This study is for people with early-stage liver cancer (hepatocellular carcinoma or HCC) and low albumin levels (hypoalbuminemia). It compares two treatments: 90Y Therasphere (a type of radiation delivered directly to the tumor) and Microwave Ablation (MWA), which uses heat to destroy the tumor. The goal is to see which treatment is better at preventing the cancer from growing or spreading within one year. You might be able to join if you are 18 or older, have an HCC diagnosis, and meet certain health criteria like good overall health and normal kidney function. The study aims to enroll 50 participants, but its current status is unclear.

Study design
This study will randomly assign 50 participants to receive either 90Y Therasphere or Microwave Ablation. This is an interventional study, meaning participants will receive a specific treatment as part of the research.
What's involved
Participants will receive either 90Y Therasphere or Microwave Ablation as their first treatment. They will then have observational follow-up for one year to collect information on their health and treatment response.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one year after their first treatment to monitor for disease progression and other outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05953961

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

Recruiting
NAAges 18+InterventionalTreatment
Ochsner Health System
~50 participants
Updated 2025-08-03 on ClinicalTrials.gov
What's tested:Therasphere 90YMicrowave Ablation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease Progression
Measured over 1-year

Conditions

Carcinoma, Hepatocellular

Explore related trials

Hepatocellular Carcinoma

NCT05953961

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ochsner Main Campus

    New Orleans, Louisianastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ari Cohen, MD · PRINCIPAL_INVESTIGATOR · Ochsner Health

Who to contact

Ken Bode
[email protected]
5048421936
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liver Diseases 2018 HCC practice guidelines
Eastern Cooperative Oncology Group score 0 - 1
Child-Pugh A - B
Bilirubin \< 2.5 mg/dL
Creatinine \< 2.0 mg/dL
No prior liver-directed therapy or systemic therapy for HCC
Solitary, unresectable HCC ≤ 3cm
Albumin level \< 3.4 g/dL at HCC diagnosis
Tumor anatomical location and angiosome amendable to MWA and 90Y

Exclusion

Pregnant women
Concurrent malignancy

What this trial measures

  • Disease Progression1-year

    Progression in disease staging according to the Barcelona Clinic Liver Cancer Staging Algorithm